drugset / Trial / NCT05036681
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
Phase 2
Terminated
9 enrolled
M.D. Anderson Cancer Center
National Comprehensive Cancer Network · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
It's propose this pilot phase 2 study to explore the combination therapy of futibatinib with pembrolizumab in patients with metastatic microsatellite stable (MSS) endometrial carcinoma to provide a well-tolerated regimen for durable responses.
Timeline
- Start
- 2021-09-30
- Primary completion
- 2024-09-30
- Completion
- 2025-05-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Futibatinib | Small molecule | — | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |